Effectiveness of emicizumab in preventing bleeding events in severe and moderate hemophilia A: A single-center experience in Bangladesh.

Emicizumab is a monoclonal antibody that bridges activated factor IX (FIX) and factor X (FX) to replace the function of missing activated factor VIII (FVIII) in hemophilia A patients irrespective of FVIII inhibitor status. This study assessed the effectiveness of emicizumab in preventing bleeding episodes in patients with hemophilia A. This observational study included patients with moderate to severe hemophilia A who were undergoing episodic FVIII replacement therapy. The primary endpoint was the difference in annualized bleeding rates (ABR) and the secondary endpoint was the difference in Hemophilia Joint Health Score (HJHS) before and after emicizumab prophylaxis. A total of 30 male hemophilia patients were included, the mean age was 16.7 (SD: ±8.1) years, and most of them had moderate hemophilia A [63.3%]. Before prophylaxis, the median ABR was 48 (interquartile range [IQR]: 35-60), and 93.3% of patients had ABR greater than eight, whereas after prophylaxis the median ABR decreased significantly (median [IQR]: 0 [0.0-0.4], p < 0.001), and 56.7% had zero bleeds. ABR was not significantly different in patient with and without FVIII inhibitors. The HJHS scores significantly improved after prophylaxis (10 vs. 2.5, p < 0.001). The bleeding events were reduced significantly (23 vs. 0.0, p < 0.001), and zero new target joints were reported after prophylaxis. Most of the patients [93.3%] did not face any serious adverse events after prophylaxis. Emicizumab prophylaxis was associated with a significantly lower rate of bleeding events among participants with hemophilia A, regardless of inhibitor status.

Atomic layer deposition of lithium zirconium oxides for the improved performance of lithium-ion batteries.

Recently there has been increasing interest to develop lithium-containing films as solid-state electrolytes or surface coatings for lithium-ion batteries (LIBs) and related systems. In this study, we for the first time investigated the thin film growth of lithium zirconium oxides (LixZryO or LZOs) through combining two individual atomic layer deposition (ALD) processes of ZrO2 and LiOH, i.e., sub-ALD of ZrO2 and LiOH. We revealed that the hygroscopic nature of the LiOH component has a big impact on the growth of LZOs. We found that an increased temperature to 225 °C was more effective than an elongated purge to mitigate the adverse effects of physisorbed H2O. We further discovered that, during the resultant LZO super-ALD processes, the growth of sub-ALD LiOH has been promoted while the growth of sub-ALD ZrO2 has been inhibited. In this study, a suite of instruments has been applied to characterize the LZO super-ALD processes and the resultant LZO films, including in situ quartz crystal microbalance (QCM), scanning electron microscopy (SEM), scanning transmission electron microscopy (STEM), atomic force microscopy (AFM), synchrotron-based X-ray diffraction (XRD), and X-ray photoelectron spectroscopy (XPS). Furthermore, we applied the resulting LZO films over LiNi0.6Mn0.2Co0.2O2 (NMC622) cathodes in LIBs and demonstrated that the LZO coating films could evidently improve the lithium-ion insertion and extraction rates of the NMC622 electrodes up to 3.4 and 2.6 times, respectively. The LZO-coated NMC622 cathodes exhibited much better performance than the uncoated NMC622 ones.

Snakeskin-Inspired Elastomers with Extremely Low Coefficient of Friction under Dry Conditions.

Soft elastomers are critical to a broad range of existing and emerging technologies. One major limitation of soft elastomers is the large friction of coefficient (COF) due to inherently large adhesion and internal loss. In applications where lubrication is not applicable, such as soft robotics, wearable electronics, and biomedical devices, elastomers with inherently low dry COF are required. Inspired by the low COF of snakeskins atop soft bodies, this study reports the development of elastomers with low dry COF by growing a hybrid skin layer with a strong interface with a large stiffness gradient. Using a solid-liquid interfacial polymerization (SLIP) process, hybrid skin layers are imparted onto elastomers, which reduces the COF of the elastomers from 1.6 to 0.1, without sacrificing the bulk compliance and ductility of elastomer. Compared with existing surface modification methods, the SLIP process offers spatial control and ability to modify flat, prepatterned, curved, and inner surfaces, which is essential to engineer multifunctional skin layers for emerging applications.